Amicus Therapeutics — Investor Presentation (July 2019)
42 slides from Amicus Therapeutics's investor presentation, Jul 9, 2019
Slide 1: Forward-Looking Statements
General Corporate & Gene Therapy Overview 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporti
Slide 2: Amicus: leading global rare disease biotechnology company
General Corporate & Gene Therapy Overview 3 Biologics AT-GAA Phase 3 in Pompe Disease GLOBAL COMMERCIAL ORGANIZATION Global Drug Development ~$580M+ Cash as of 6/30/19 (Proforma) Robust R&D Engine Nearly 50+ Lysosomal Disorders and More Prevalent Rare Diseases 600+ EMPLOYEES in 27 Countries Amicus i
Slide 3: Gene Therapy Portfolio Industry's Largest for Rare Disease
General Corporate & Gene Therapy Overview 4 Gene Therapy Portfolio Industry’s Largest for Rare Disease Pompe Biologic Phase 3 with Breakthrough Therapy Designation Galafold Precision Medicine for Fabry Disease Amicus has built a deep and highly distinct “Rare Portfolio” of products, technologies and
Slide 4: Creating Shareholder Value
General Corporate & Gene Therapy Overview 5 Creating Shareholder Value While Amicus shares have appreciated more than ~600% over the past five years, there is now an opportunity for further and substantial shareholder value creation
Slide 5: Galafold Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease
Slide 6: Galafold: Precision Medicine for Fabry Disease Snapshot
Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of March 31, 2019) $160-180M FY19 Global Galafold Rev. Guidance $34.0M 1Q19 Galafold Revenue 24 Countries with Pricing & Reimbursement Geographic Expansion in 2019 8 Regulatory Approvals 348 Amenable Variants in U.S. Label Galafo
Slide 7: Galafold Global Launch Momentum
Galafold: Precision Medicine for Fabry Disease 8 Galafold Global Launch Momentum (as of March 31, 2019) Global: 150+ new patient adds in 1Q19 with continued >90% compliance and adherence. Now estimate ~18% global market share of treated amenable patients* U.S: 200+ prescription referral forms (PRFs)
Slide 8: Galafold Success and FY19 Revenue Guidance
Galafold: Precision Medicine for Fabry Disease 9 Galafold Success and FY19 Galafold Revenue Guidance $500M+ $160M-$180M $91.2M $36.9M $5.0M FY16 FY17 FY18 FY19 FY23 Galafold sales in 2019 represent the first full year of launch in the major geographies in the world and will be between $160-$180M, wi
Slide 9: Total Amenable Patient Population for Galafold
Galafold: Precision Medicine for Fabry Disease 10 Total Amenable Estimate based on 35% - 50% amenability Patient Population (“TAPP”) Upside Potential WORLDWIDE Diagnosis grows due to newborn screening and patient finding initiatives in U.S. & Japan TAPP: 4,700-6,750 Peak Potential WORLDWIDE Diagnosi
Slide 10: AT-GAA Novel ERT for Pompe Disease
AT-GAA Novel ERT for Pompe Disease
Slide 11: Pompe Disease Overview
AT-GAA for Pompe Disease 12 Pompe Disease Overview 5,000 – 10,000+ patients diagnosed WW1; newborn screening suggests underdiagnosis Respiratory and cardiac failure are leading causes of morbidity and mortality Age of onset ranges from infancy to adulthood Deficiency of GAA leading to glycogen accum
Slide 12: AT-GAA: Foundation in Protein Engineering
AT-GAA for Pompe Disease 13 AT-GAA: Foundation in Protein Engineering Amicus scientists specializing in protein engineering and glycobiology created a uniquely glycosylated and highly phosphorylated ERT (AT-GAA) that significantly enhances targeting to key muscles affected in patients.
Slide 13: Pompe Patient Experience in Phase 1/2 Study
AT-GAA for Pompe Disease 14 Pompe Patient Experience in Phase 1/2 Clinical Study (ATB200-02) 6-Minute Walk Test (m) Change at Month 24 Cohort Baseline (n=10) (n=5) Mean (SD) FVC (% Predicted) Change at Month 24 Cohort Baseline (n=9*) (n=5) Mean (SD) aOne patient in Cohort 1 discontinued from study (
Slide 14: PROPEL Study Design
AT-GAA for Pompe Disease 15 PROPEL (ATB200-03) Study Design 52-Week Primary Treatment Period (Double-Blind) 2:1 Randomization BTD Criteria • Preliminary clinical evidence indicates drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints AT
Slide 15: Pompe Biologics Manufacturing
AT-GAA for Pompe Disease 16 Pompe Biologics Manufacturing • Agreements on biocomparability with key regulators (FDA, BfARM) • PROPEL participants now treated with drug manufactured at 1000L • Current bioreactor capacity to supply global population Amicus and partner WuXi Biologics have successfully
Slide 16: AT-GAA Treatment Opportunity
AT-GAA for Pompe Disease 17 AT-GAA Treatment Opportunity • Phase 1/2 study data on AT-GAA demonstrated profound improvement in functional outcomes for Pompe patients • Enrollment of pivotal Phase 3 PROPEL Trial on track to complete enrollment of at least 100 patients by year end • Ongoing studies in
Slide 17: AT-GAA Treatment Opportunity
AT-GAA for Pompe Disease 18 AT-GAA Treatment Opportunity Any Pompe Gene Therapy will have to address both muscular and CNS aspects of disease and compare favorably on clinical endpoints to the then approved standard of care. AT-GAA has the potential to be standard of care well into the 2030s
Slide 18: AT-GAA Treatment Opportunity
AT-GAA for Pompe Disease AT-GAA Treatment Opportunity Any Pompe Gene Therapy will have to address both muscular and CNS aspects of disease and compare favorably on clinical endpoints to the then approved standard of care. AT-GAA has the potential to be standard of care well into the 2030s
Slide 19: A Natural Evolution: Chaperones to Optimized ERT to Gene Therapy
General Corporate & Gene Therapy Overview 20 A Natural Evolution: Chaperones to Optimized ERT to Gene Therapy Pharmacological Chaperones Next-Generation ERTs Gene Therapies Stabilize “naturally produced” enzymes Stabilize and target “externally produced” enzymes Stabilize and target “internally prod
Slide 20: Expansion in Gene Therapy
General Corporate & Gene Therapy Overview 21 Expansion in Gene Therapy DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) monotherapy Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) Pompe Gene Therapy PENN Batten Franchise – Gen
Slide 21: Validated Gene Therapy Platform
General Corporate & Gene Therapy Overview 22 Validated Gene Therapy Platform Clinically validated AAV gene therapy approach by Dr. Brian Kaspar and team at NCH and Sanford – Nationwide Children’s Hospital Center for Gene Therapy (NCH) – Intrathecal delivery with robust expression throughout CNS Prec
Slide 22: Batten Disease Overview
General Corporate & Gene Therapy Overview 23 Batten Disease Overview Disease Overview • A group of disorders known as neuronal ceroid lipofuscinoses (NCLs), collectively referred to as Batten disease Mutation in one of 13 different CLN genes leads to lysosomal dysfunction Signs and symptoms include:
Slide 23: AAV-CLN6 Batten Disease Gene Therapy: Phase 1/2 Study
AAV-CLN6 Gene Therapy for CLN6-Batten Disease 24 AAV-CLN6 Batten Disease Gene Therapy: Phase 1/2 Study 1st Patient Dosed >3 Years Ago 12 Children Treated Favorable Safety Profile (exposure from ~7 to 41 months) The Amicus CLN6 Batten disease program is one of the most advanced AAV Gene Therapy progr
Slide 24: Efficacy Data: Matched Sibling Case Report
AAV-CLN6 Gene Therapy for CLN6-Batten Disease 25 Efficacy Data: Matched Sibling Case Report Hamburg Score (Motor and Language) Younger sibling AGE OF ONSET • Two siblings (same genotype) treated with gene therapy at ages 2.8 and 5.3 years, respectively Two years post treatment, Hamburg motor and lan
Slide 25: Upcoming CLN6 Batten Disease Interim Clinical Data
AAV-CLN6 Gene Therapy for CLN6-Batten Disease 26 Upcoming CLN6 Batten Disease Interim Clinical Data 1 Safety 2 Hamburg Motor + Language (study patients) 3 Hamburg Motor + Language (natural history) 4 Matched Sibling Pairs (treated vs. natural history*; treated vs. treated**) *study participants with
Slide 26: CLN3 Batten Disease: Preclinical and Clinical Summary
AAV-CLN3 Gene Therapy for CLN3-Batten Disease 27 CLN3 Batten Disease: Preclinical and Clinical Summary Preclinical Data in KO Mice Amicus’ second clinical stage Gene Therapy in CLN3 Batten disease has successfully completed dosing in three children in Cohort 1 (low dose) and dosing for up to an addi
Slide 27: Addressable Patient Populations in Neurologic LDs
General Corporate & Gene Therapy Overview 28 Addressable Patient Populations in Neurologic LDs* >3,500 CLN1, Tay-Sachs, and Others ~750 CLN8 ~5,000 CLN3 ~1,000 CLN6 *Estimated addressable U.S., EU, Japan, and other major, reimbursable markets based on published incidence and prevalence The portfolio
Slide 28: Amicus Establishes Gene Therapy Portfolio
Amicus and Penn Expanded Gene Therapy Collaboration 29 Amicus Establishes Gene Therapy Portfolio Increased Protein Expression Increased Protein Secretion Improved Protein Targeting & Stabilization Novel untranslated sequences to avoid inhibition of initiation and drive efficient protein synthesis Ef
Slide 29: Penn Collaboration Overview
Amicus and Penn Expanded Gene Therapy Collaboration 30 Penn Collaboration Overview • Dr. James Wilson and Gene Therapy Program (GTP) at Penn: Renowned center of excellence Gene therapy for orphan diseases – >20 years of gene therapy experience – Proven platform with numerous clinical programs across
Slide 30: Preclinical Pompe Gene Therapy Results
Amicus and Penn Expanded Gene Therapy Collaboration 31 Preclinical Pompe Gene Therapy Results Glycogen Luxol/PAS – Spinal Cord Vehicle AAV.hGAA nat AAV.hGAA eng Wild-Type Gaa -/-Gaa -/-Gaa -/-Gaa +/+ Key findings: • • Improved cellular uptake and glycogen reduction observed with engineered AAV-hGAA
Slide 31: Amicus Gene Therapy Expansion: Key Takeaways
Amicus and Penn Expanded Gene Therapy Collaboration 32 Amicus Gene Therapy Expansion: Key Takeaways Amicus to Invest $10M / Year for 5 Years for Research to Improve Safety, Efficacy and Manufacturability of Next Generation Vectors with Option to Extend Partnership Encompasses 12 Additional Rare Dise
Slide 32: Engineered Transgenes for Optimal Cross-Correction
Amicus and Penn Expanded Gene Therapy Collaboration 33 Amicus Approach: Engineered Transgenes for Optimal Cross-Correction (4) Proteins include targeting moieties for improved uptake Transgene encapsulated in AAV Target protein enters target cell via receptor binding DNA (transgene) Modified AAV inj
Slide 33: MPS IIIB Program Summary
Amicus and Penn Expanded Gene Therapy Collaboration 34 MPS IIIB Program Summary AAV-NAGLU Candidate (Unmodified WT): KO Mouse* NAGLU Binding to Intended Receptor** Brain NAGLU Activity Brain Histopath Score [unaffected] • AAV-NAGLU candidate (unmodified); 3 single ICV doses (LD, MD, HD) • 4-mo old K
Slide 34: Preclinical Advancements in GTx to come in 2H 2019
General Corporate & Gene Therapy Overview 35 Preclinical Advancements in GTx to come in 2H 2019 Positive initial preclinical data for Pompe gene therapy Selection of CMO partners for initial manufacturing supply Complete enrollment in low-dose cohort in CLN3 Batten disease Phase 1/2 study Complete e
Slide 35: Global Research and Gene Therapy Center of Excellence in Philadelphia
General Corporate & Gene Therapy Overview 36 Amicus Global Research and Gene Therapy Center of Excellence in Philadelphia Artist renderings The 75,000 sq. ft. Amicus Global Research & Gene Therapy Center of Excellence in Philadelphia will be fully operational in 2H 2019 and is adjacent to Penn’s cam
Slide 36: Manufacturing and Process Science
General Corporate & Gene Therapy Overview 37 Manufacturing and Process Science Manufacturing and process science capabilities and capacity in Gene Therapy will be crucial for Amicus success. Our experience in complex biologics manufacturing and quality control provide a great competitive advantage h
Slide 37: CMO Partnerships
General Corporate & Gene Therapy Overview 38 CMO Partnerships GENE THERAPY Technologies and capabilities for Batten disease programs are being transferred to and developed at Thermo Fisher’s viral vector services business CLN6 Batten disease gene therapy to undergo a similar GMP process for clinical
Slide 38: Plasmid Supply Relationships
General Corporate & Gene Therapy Overview 39 Plasmid Supply Relationships Amicus has also established long term supply agreements with industry leading plasmid suppliers for research and GMP quality plasmids for all Amicus Gene Therapy programs.
Slide 39: Amicus Manufacturing Center of Excellence
General Corporate & Gene Therapy Overview 40 Amicus Manufacturing Center of Excellence Amicus will build, staff and operate our own state of the art Gene Therapy Manufacturing Center of Excellence. This manufacturing complex will become one of the largest, most flexible and most technically advanced
Slide 40: Financial Summary and Guidance
General Corporate & Gene Therapy Overview 41 Financial Summary and Guidance Cash (Proforma) ~$580M Cash Runway1 Into 2021 Debt2 $152.8M Shares Outstanding3 ~255M FY19 Galafold Revenue Guidance 1Based on existing operating plan including proceeds from June 2019 equity offering to invest in manufactur
Slide 41: Our Passion for a Difference Unites Us
General Corporate & Gene Therapy Overview 42 Our Passion for a Difference Unites Us Amicus is now at a major inflection point and positioned to create significant shareholder value ahead while advancing our mission for patients.
Slide 42: Our Passion for Making a Difference Unites Us
General Corporate & Gene Therapy Overview Our Passion for Making a Difference Unites Us Amicus is now at a major inflection point and positioned to create significant shareholder value ahead while advancing our mission for patients.
Amicus Therapeutics — Investor Presentation (July 2019) on 6ix